Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06348264
Status:
RECRUITING
Last Update Posted:
2024-04-04
First Post:
2024-03-30
Brief Title:
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive High-risk Salivary Duct Carcinoma
Sponsor:
Organization:
Peking University First Hospital